CN110693917B - Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 - Google Patents
Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 Download PDFInfo
- Publication number
- CN110693917B CN110693917B CN201911126003.9A CN201911126003A CN110693917B CN 110693917 B CN110693917 B CN 110693917B CN 201911126003 A CN201911126003 A CN 201911126003A CN 110693917 B CN110693917 B CN 110693917B
- Authority
- CN
- China
- Prior art keywords
- akkermansia
- bacteria
- polyciniphila
- depression
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000702462 Akkermansia muciniphila Species 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000000935 antidepressant agent Substances 0.000 title description 4
- 230000001430 anti-depressive effect Effects 0.000 title description 2
- 229940005513 antidepressants Drugs 0.000 title description 2
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 241000702460 Akkermansia Species 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 208000004232 Enteritis Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 208000020401 Depressive disease Diseases 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 239000013613 expression plasmid Substances 0.000 claims description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 208000028774 intestinal disease Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000012148 binding buffer Substances 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000009019 intestinal benign neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 58
- 238000002474 experimental method Methods 0.000 abstract description 36
- 230000000994 depressogenic effect Effects 0.000 abstract description 30
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 13
- 238000002054 transplantation Methods 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 11
- 230000009182 swimming Effects 0.000 abstract description 10
- 239000000725 suspension Substances 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000035882 stress Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000009928 pasteurization Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000754688 Cercaria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种Akkermansia Muciniphila菌在制备防治抑郁症的药物或保健品中的应用。本发明对Akkermansia Muciniphila菌在抑郁发病和抗抑郁中的作用进行了体内药效学研究,结果显示抑郁症患者肠道内的Akkermansia Muciniphila丰度明显降低。动物实验结果显示,抑郁小鼠肠道Akkermansia Muciniphila丰度显著降低。本发明对抑郁小鼠模型给予Akkermansia Muciniphila菌移植,实验表明,Akkermansia Muciniphila菌移植可提升小鼠的运动距离并减少悬尾实验和强迫游泳实验的不动时间,显著缓解小鼠的抑郁状态,显示出了很好的抗抑郁疗效,且未见副作用。
Description
技术领域
本发明涉及一种益生菌,具体涉及Akkermansia Muciniphila在抗抑郁药物或者保健品中的新用途,属于医药技术领域。
背景技术
抑郁症是以持久而显著的心境低落为主要临床特征的精神类疾病。其临床常伴有心境低落,自卑抑郁,甚至自杀企图或行为,并且多数患者有反复发作的倾向。因此,抑郁症是一种高致残率的疾病。根据世界卫生组织(WHO)报道,在一般人群中每100人就有15人受到过抑郁症的困扰。每年用于抑郁症治疗的费用占医疗总支出的12.3%。而在中国,估计有2000万-5000万的抑郁症患者,并且患病率逐年增长,目前市场尚未安全有效的抗抑郁生物制剂。
尽管抑郁症的发病与遗传、神经内分泌、神经免疫、体液等因素密切相关,但是其确切的病因并不清楚。近年来大量研究表明,肠道菌群在抑郁症发病过程中扮演着重要的角色。肠道菌群通过“肠-脑轴”影响着大脑的功能及行为。临床研究发现,抑郁症患者粪便中放线菌,乳杆菌,链球菌,尾蚴梭菌等细菌显著升高以及拟杆菌,酸球菌,韦荣球菌等细菌显著降低,动物实验研究表明,将抑郁患者的粪便移植给无菌小鼠,小鼠呈现抑郁样行为。
Akkermansiamuciniphila是一种2004年被鉴定出来的菌种,是人类消化道中普遍存在的共生菌,约占比3-5%。Akkermansiamuciniphila已被证实与肥胖,二型糖尿病,孤独症等慢性疾病密切相关。然而,还未见其在防治抑郁症中的报道。
发明内容
发明目的:本发明在Akkermansiamuciniphila现有用途的基础上,通过临床检测数据分析和动物实验筛选其临床功效,开发其在制备防治抑郁症及其抑郁症合并其它疾病的药物或保健品中的新应用。
技术方案:为了实现以上目的,本发明采取的技术方案为:
Akkermansia Muciniphila菌在制备预防和治疗抑郁症的药物或保健品中的应用。
Akkermansia Muciniphila菌在制备预防和治疗肠道疾病合并抑郁症的药物或保健品中的应用。作为优选,所述的肠道疾病包括肠炎、肠道肿瘤。
Akkermansia Muciniphila菌在制备预防和治疗糖尿病合并抑郁症的药物或保健品中的应用。
Akkermansia Muciniphila菌在制备预防和治疗高血压合并抑郁症的药物或保健品中的应用。
Akkermansia Muciniphila菌在制备预防和治疗肥胖合并抑郁症的药物或保健品中的应用。
Akkermansia Muciniphila菌在制备预防和治疗癫痫合并抑郁症的药物或保健品中的应用。
一种具有防治抑郁症的生物制剂,它包括Akkermansia Muciniphila菌或者Akkermansia Muciniphila菌提取物。
作为优选,以上所述的应用,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
一种具有防治抑郁症的生物制剂,所述的Akkermansia Muciniphila菌的提取物为Amuc_1100蛋白。
作为优选方案,Amuc_1100蛋白的制备方法为:
通过扩增编码1100胞内部分的基因,将所得的PCR产物通过酶切酶连的方法克隆到pET32aTEV载体上,构建融合His标签的Amuc_1100的表达质粒,并将其转化到大肠杆菌C43(DE3)感受态中.将该菌株接种在含有100ug/ml氨苄西林的LB培养液中,37℃、1800rpm培养,在指数中期(0D600=1.0)时添加0.5mM IPTG,28℃、180rpm诱导3h;4000rpm离心10分钟沉淀细胞,Binding buffer重悬沉淀细胞,并加入终浓度为1mM的PMSF,使用高压均质机将细胞裂解;将细胞裂解液离心12000rpm、30min、4℃,收集上清;通过Ni-16NTA His·Bind树脂亲和层析纯化得到Amuc_1100蛋白。
有益效果:本发明和现有技术相比具有以下优点:
(1)本发明在临床检测数据分析基础上,通过大量的动物实验筛选,深入研究,提供Akkermansia Muciniphila在抗抑郁药物中的新用途。本发明采用菌群敲除和粪菌移植技术,实验结果表明,Akkermansia Muciniphila移植可以提升小鼠的运动距离并减少悬尾实验和强迫游泳实验的不动时间,显著缓解小鼠的抑郁状态,提示AkkermansiaMuciniphila有很好的抗抑郁疗效,临床上可以用于制备治疗抑郁症的药物。并且实验发现对肠炎合并抑郁模型小鼠具有很好的防治作用。
(2)实验结果表明Akkermansia Muciniphila,疗效可靠,使用安全,无毒副作用,可以用于制备防治抑郁的药品或保健食品。
(3)本发明发现,Akkermansia Muciniphila活菌或经过巴氏消毒死菌,对于代谢疾病患者均显示较好有效,而且安全。本发明经过对比发现,对于抑郁患者同样安全,而且活菌和死菌同样有效。
附图说明
图1为慢性束缚应激导致小鼠抑郁样状态对菌群及Akkermansia Muciniphila相对丰度的影响图。
图2为实施例1旷场实验结果图。(正常组比较,*P<0.05;与抑郁组比较,#P<0.05)
图3为实施例1悬尾实验结果图(与正常组比较,*P<0.05;与抑郁组比较,#P<0.05)。
图4为实施例1强迫游泳实验结果图(与正常组比较,*P<0.05;与抑郁组比较,#P<0.05)。
图5为实施例2旷场实验结果图。
图6为实施例2悬尾实验结果图。
图7为实施例2强迫游泳实验结果图。
图8为实施例2各组的小鼠结肠长度的实验结果图。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施例所描述的具体的物料配比、工艺条件及其结果仅用于说明本发明,而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1
1、Akkermansia Muciniphila菌液的制备方法:
取1ml的Akkermansia Muciniphila菌液,加入10ml的脑心浸出液肉汤中,于37℃厌氧环境下培育72h后,将菌液离心(6000rpm)20分钟,分离上清液,用无菌PBS溶液将菌液调配至OD600=1,得到Akkermansia Muciniphila菌液(简称AKK菌液)。
2、巴氏消毒AKK菌(死菌)制备方法
将步骤1得到的AKK菌液放置于水浴箱中加热到62-65℃,保持30分钟。
3、Amuc_1100制备方法
通过扩增编码1100胞内部分的基因,将所得的PCR产物通过酶切酶连的方法克隆到pET32aTEV载体上,构建融合His标签的Amuc_1100的表达质粒,并将其转化到大肠杆菌C43(DE3)感受态中.将该菌株接种在含有100ug/ml氨苄西林的LB培养液中,37℃、1800rpm培养,在指数中期(0D600=1.0)时添加0.5mM IPTG,28℃、180rpm诱导3h;4000rpm离心10分钟沉淀细胞,Binding buffer重悬沉淀细胞,并加入终浓度为1mM的PMSF,使用高压均质机将细胞裂解;将细胞裂解液离心12000rpm、30min、4℃,收集上清;通过Ni-16NTA His·Bind树脂亲和层析纯化得到Amuc_1100蛋白。
2、临床粪便样本制备方法:
选取已收集的健康及抑郁志愿者粪便各5份,对于每组粪便样本进行混样处理,将混样处理的粪便溶于无菌PBS中,将菌液离心(1000rpm)10分钟,取出上清备用。
3、肠道菌群敲除造模
取6-8周C57BL/6雄性小鼠每日常规饮用广谱抗生素,持续4周。广谱抗生素包含氨苄西林(Ampicillin,1g/l)、甲硝唑(Metronidazole,1g/l)、新霉素(Neomycin,1g/l)或万古霉素(Vancomycin,500mg/l)。
4、粪菌移植
在肠道菌群敲除造模结束后,将C57BL/6小鼠30只,随机分为5组,每组10只,分别为正常组、抑郁组、AKK治疗组、巴氏消毒AKK菌治疗组和Amuc_1100蛋白治疗组,正常组小鼠每日给予健康人粪菌0.1ml和无菌PBS溶液0.1ml;抑郁组小鼠每日给予抑郁患者粪菌0.1ml和无菌PBS溶液0.1ml;AKK治疗组小鼠每日给予抑郁患者粪菌0.1ml和AKK菌液0.1ml,巴氏消毒AKK菌治疗组小鼠每日给予抑郁患者粪菌0.1ml和巴氏消毒AKK菌液0.1ml,Amuc_1100蛋白治疗组小鼠每日给予抑郁患者粪菌0.1ml和Amuc_1100蛋白(3μg/只)。持续14天。在粪菌移植造模结束后对小鼠进行行为学检测,行为学检测包括:旷场实验,悬尾实验和强迫游泳实验。
5、小鼠行为学检测
(1)旷场实验
将小鼠放入黑色木箱中(45cmx45cmx45cm)小室的角落,适应1分钟后,用视频计算机跟踪系统记录之后5分钟所有自发活动。以总运动距离作为运动活动的指标。
(2)悬尾实验
胶带放置在距尾端约2厘米处,将小鼠悬挂在距离地面50cm处。每只小鼠放置6min,并在最后4min以秒为单位记录小鼠不动时间。不动时间被定义为没有逃避导向的行为。当小鼠没有任何身体运动时,它们被认为是静止的。。
(3)强迫游泳实验
小鼠放置在30cm×45cm水箱中,水温保持在27℃。每只小鼠放置6min,并在最后4min以秒为单位记录小鼠不动时间。不动时间是指动物在水中漂浮而不挣扎,只需做一些动作就能保持头部高于水面的时间。随后,实验小鼠被置于取暖灯下晾干。
6、构建慢性束缚应激模型
构建慢性束缚应激抑郁小鼠模型(Chronic restraint stress,CRS)。CRS是当前国内外较为公认的抑郁模型,具体的造模方法为:取雄性C57BL/6小鼠,年龄在6-8周。适应性喂养1周后,每日将小鼠置放在0.5mm直径,50ML的离心管内3h,持续30天。在第30天记录行为测试结果。在CRS造模期间,其余各组限制小鼠喂食和给水。
7、Akkermansia Muciniphila菌群样本提取
按照制造商的说明,应用DNA提取工具(Omega Bio-tek,Norcross,GA,U.S.),将上述的临床健康人群和抑郁患者粪便样本及慢性束缚应激实验复制的抑郁状态小鼠盲肠内容物样本进行DNA提取。应用Nano-Drop 1000分光光度计(Thermo ScientificInc.,Wilmington,DE,USA)确定DNA浓度。通过F338(5′-ACTCCTACGGGAGGCAGCA-3′)和R806(5′-GGACTACHVGGGTWTCTAAT-3′)引物对细菌16s rRNA基因V3-V4可变区域进行扩增。每个样本3个重复,将同一样本的聚合酶链反应(Polymerase Chain Reaction,PCR)产物混合后用2%琼脂糖凝胶电泳检测,使用AxyPrepDNA凝胶回收试剂盒(AXYGEN公司)切胶回收PCR产物,Tris_HCl洗脱;2%琼脂糖电泳检测。扩增子从2%琼脂糖胶中提取。所有的PCR产物通过AxyPrep DNA凝胶萃取设备(Axygen Biosciences公司)进行提纯。参照电泳初步定量结果,将PCR产物用QuantiFluorTM-ST蓝色荧光定量系统(Promega公司)进行检测定量,之后按照每个样本的测序量要求,进行相应比例的混合。在Illumina MiSeq平台上对萃取的PCR产物进行等分子、250bp双端测序分析。原始焦磷酸测序序列上传到NCBI数据中心的数据库SRA(Sequence Read Archive)。
8、Akkermansia Muciniphila菌群分析
对上述7提取得到的菌群样本进行菌群分析;采用高质量的序列合并重叠生成fastq文件。通过QIIME(version 1.9.1)软件将输出的fastq文件进行多路解码和质控过滤。质控过滤标准为:(1)过滤read尾部质量值20以下的碱基,设置50bp的窗口,如果窗口内的平均质量值低于20,从窗口开始截去后端碱基,过滤质控后50bp以下的read;(2)根据PEreads之间的overlap关系,将成对reads拼接(merge)成一条序列,最小overlap长度为10bp;(3)拼接序列的overlap区允许的最大错配比率为0.2,筛选不符合序列;(4)根据序列首尾两端的barcode和引物区分样品,并调整序列方向,barcode允许的错配数为0,最大引物错配数为2;应用UCHIME软件将嵌合体序列去除,并通过UPARSE(version 7.1http://drive5.com/uparse/)软件将97%相似性的截点聚合生成OUTs。通过RDA分类器(http://rdp.cme.msu.edu/)并和silva(SSU115)16S rRNA数据库比对将每个OUT(门水平和属水平)进行比对分类。
9、统计分析
10、实验结果
(1)按以上菌群分析方法,检测分析健康人群和抑郁患者的AkkermansiaMuciniphila相对丰度。如表1所示,抑郁患者Akkermansia Muciniphila较健康人群丰度均值显著降低,提示Akkermansia Muciniphila降低是患者抑郁致病的因素之一。
表1.抑郁症对菌群中Akkermansia Muciniphila相对丰度的影响
*p<0.05与健康人群比较
(2)如表2和图1所示,慢性束缚应激实验复制小鼠抑郁状态,菌群检测发现Akkermansia Muciniphila菌丰度显著减低,进一步验证Akkermansia Muciniphila降低可能是患者抑郁致病主要因素之一。
表2慢性束缚应激导致小鼠抑郁样状态对菌群及Akkermansia Muciniphila相对丰度的影响
*p<0.05与空白组比较
(3)抑郁患者粪菌移植实验发现,移植小鼠出现抑郁状态,提示肠道菌群与抑郁关系密切,但在口服上述AKK菌后,能有效改善小鼠的抑郁状态。
如图2所示,在旷场实验中,与正常组比较,抑郁组小鼠运动总距离显著降低(P<0.05)。与抑郁组比较,AKK菌治疗组、巴氏消毒AKK菌治疗组和Amuc_1100蛋白治疗组小鼠运动总距离显著增加(P<0.05)。
如图3所示,在悬尾实验中,与正常组比较,抑郁组小鼠的不动时间显著升高(P<0.05),与抑郁组比较,AKK菌治疗组、巴氏消毒AKK菌治疗组和Amuc_1100蛋白治疗组小鼠不动时间显著降低(P<0.05)。
如图4所示,在强迫游泳实验中,与正常组比较,抑郁组小鼠的不动时间显著升高(P<0.05),与抑郁组比较,AKK菌治疗组、巴氏消毒AKK菌治疗组和Amuc_1100蛋白治疗组小鼠不动时间显著降低(P<0.05)。
如上述实验结果表明,将AKK菌缺乏的抑郁患者粪便移植给肠道菌群敲除鼠,小鼠呈抑郁样状态。经口服AKK活菌和巴氏消毒AKK菌及其Amuc_1100蛋白治疗后,小鼠的抑郁状态显著改善。以上结果表明,本发明提供的AKK菌及其Amuc_1100蛋白具有很好的抗抑郁的功效。本发明筛选的Akkermansia Muciniphila菌或巴氏消毒后的死菌不仅可以作为食品、保健品中使用,也可以用于制备药品,既有治疗作用,也有预防作用。
本发明研究表明,Akkermansia Muciniphila菌不仅对抑郁症患者有效,而且对一般人群抑郁状态有效。
实施例2考察AKK菌对抑郁合并肠炎模型小鼠的治疗作用
1、构建慢性束缚应激抑郁小鼠模型(Chronic restraint stress,CRS)CRS具体的造模方法为:取雄性C57BL/6小鼠,年龄在6-8周。适应性喂养1周后,每日将小鼠置放在0.5mm直径,50ML的离心管内3h,持续30天。在第30天记录行为测试结果。在CRS造模期间,其余各组限制小鼠喂食和给水;实验结束对所有小鼠进行行为学检测,行为学检测包括:旷场实验,悬尾实验和强迫游泳实验。行为学检测显示抑郁造模成功后,立即处死小鼠并取出盲肠内容物。随机将3只小鼠的盲肠内容物进行混样处理,溶于无菌PBS中,将菌液离心(1000rpm)10分钟,取出上清备用。
2、肠道菌群敲除造模
取6-8周C57BL/6雄性小鼠每日常规饮用广谱抗生素,持续4周。广谱抗生素包含氨苄西林(Ampicillin,1g/l)、甲硝唑(Metronidazole,1g/l)、新霉素(Neomycin,1g/l)或万古霉素(Vancomycin,500mg/l)。
3、粪菌移植(FMT)
3.1、在肠道菌群敲除造模结束后,将C57BL/6小鼠30只,随机分为3组,每组10只,分别为正常组、抑郁组、AKK治疗组,正常组小鼠每日给予正常小鼠粪菌0.1ml和无菌PBS溶液0.1ml;抑郁组小鼠每日给予上述1的CRS小鼠粪菌0.1ml和无菌PBS溶液0.1mL;AKK治疗组小鼠每日给予CRS小鼠粪菌0.1ml和AKK菌液0.1ml。持续14天。在粪菌移植造模结束后对小鼠进行行为学检测,行为学检测包括:旷场实验、悬尾实验和强迫游泳实验。
3.2、行为学检测实验结束后,将上述30只C57BL/6小鼠,给与含2.5%DSS的饮用水自由饮水7天,构建肠炎合并抑郁小鼠模型。然后处死小鼠,取血、结直肠组织,测量结肠长度。用10%中性福尔马林固定,常规取材,脱水,石蜡包埋。切片经HE染色等处理。
4、实验结果
4.1行为学检测结果:
如图5旷场实验,经粪菌移植(FMT),和正常组比较,抑郁组小鼠运动总距离显著降低。与抑郁组比较,AKK组小鼠运动总距离显著增加。(P<0.05)。
如图6悬尾实验,经粪菌移植(FMT),和正常组比较,抑郁组小鼠不动时间显著增加。和抑郁组比较,AKK组小鼠不动时间显著降低。(P<0.05)。
如图7强迫游泳实验,经粪菌移植(FMT),和正常组比较,抑郁组小鼠不动时间显著增加。和抑郁组比较,AKK组小鼠不动时间显著降低。(P<0.05)
4.2对肠炎检测结果
如图8所示,经粪菌移植(FMT)和DSS诱导肠炎,和正常小鼠造模的肠炎组比较,抑郁组肠炎小鼠的结肠长度显著降低。和抑郁组肠炎小鼠比较,AKK治疗组小鼠结肠长度显著增加(P<0.05)。
且由结肠病理观察结果表明,单个肠炎组小鼠结肠炎症严重程度为轻至中度;而抑郁组肠炎小鼠结肠炎症严重程度为中度,多数累及粘膜层和粘膜下层,个别的累及肌层,炎症严重程度为中度,炎细胞类型主要为单核巨噬细胞和中性粒细胞及嗜酸性粒细胞。而AKK治疗组结肠炎症较抑郁组明显减轻,粘膜下层、肌层、浆膜层无明显充血、水肿,无明显炎细胞浸润。
本发明实验过程中,小鼠移植AkkermansiaMuciniphila菌前后安全性检测提示该菌种移植安全有效。本发明对AkkermansiaMuciniphila菌移植前后小鼠血常规、肝功能、肾功能、脾脏病理、肝脏病理进行了检测,未发现毒副作用。
本发明依据上述方法研究表明,Akkermansia Muciniphila菌的对抑郁症合并肠炎具有很好的防治效果。
以上实施方式只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人了解本发明内容并加以实施,并不能以此限制本发明的保护范围,凡根据本发明精神实质所做的等效变化或修饰,都应涵盖在本发明的保护范围内。
Claims (8)
1.Akkermansia Muciniphila菌在制备治疗抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
2.Akkermansia Muciniphila菌在制备治疗肠道疾病合并抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
3.Akkermansia Muciniphila菌在制备治疗糖尿病合并抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
4.Akkermansia Muciniphila菌在制备治疗高血压合并抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
5.Akkermansia Muciniphila菌在制备治疗肥胖合并抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
6.Akkermansia Muciniphila菌在制备治疗癫痫合并抑郁症的药物中的应用,其特征在于,所述的Akkermansia Muciniphila菌包括Akkermansia Muciniphila活菌或巴氏消毒后的菌。
7.根据权利要求2所述的Akkermansia Muciniphila菌在制备治疗肠道疾病合并抑郁症的药物中的应用,其特征在于,所述的肠道疾病包括肠炎、肠道肿瘤。
8.一种生物制剂在制备治疗抑郁症的药物中的应用,其特征在于,所述生物制剂包括Akkermansia Muciniphila菌的提取物;所述的Akkermansia Muciniphila菌的提取物为Amuc_1100蛋白;
所述Amuc_1100蛋白是通过以下方法制备得到的:
通过扩增编码1100胞内部分的基因,将所得的PCR产物通过酶切酶连的方法克隆到pET32aTEV载体上,构建融合His标签的Amuc_1100的表达质粒,并将其转化到大肠杆菌C43(DE3)感受态中,将该菌株接种在含有100ug/ml氨苄西林的LB培养液中,37℃、1800rpm培养,在指数中期OD600=1.0时添加0.5mM IPTG,28℃、180rpm诱导3h;4000rpm离心10分钟沉淀细胞,Binding buffer重悬沉淀细胞,并加入终浓度为1mM的PMSF,使用高压均质机将细胞裂解;将细胞裂解液离心12000rpm、30min、4℃,收集上清;通过Ni-16NTA His·Bind树脂亲和层析纯化得到Amuc_1100蛋白。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/079604 WO2021008149A1 (zh) | 2019-07-16 | 2020-03-17 | Akkermansia muciniphila在制备抗抑郁药物或者保健品中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910639110.5A CN110227085A (zh) | 2019-07-16 | 2019-07-16 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
CN2019106391105 | 2019-07-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110693917A CN110693917A (zh) | 2020-01-17 |
CN110693917B true CN110693917B (zh) | 2020-11-17 |
Family
ID=67855050
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910639110.5A Pending CN110227085A (zh) | 2019-07-16 | 2019-07-16 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
CN201911126003.9A Active CN110693917B (zh) | 2019-07-16 | 2019-11-18 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910639110.5A Pending CN110227085A (zh) | 2019-07-16 | 2019-07-16 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN110227085A (zh) |
WO (1) | WO2021008149A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111321089B (zh) * | 2018-12-17 | 2022-03-15 | 上海究本科技有限公司 | 鼠源Akkermansia muciniphila 139菌株及其用途 |
CN110227085A (zh) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
CN111690044B (zh) * | 2020-05-06 | 2022-03-01 | 中南大学湘雅二医院 | Amuc1100蛋白的用途 |
CN111938158B (zh) * | 2020-08-18 | 2023-07-07 | 广东弘元普康医疗科技有限公司 | 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物 |
WO2022094847A1 (zh) * | 2020-11-05 | 2022-05-12 | 中国科学院深圳先进技术研究院 | 工程细菌的细胞裂解液及其在肿瘤治疗中的应用 |
CN113322202B (zh) * | 2021-05-31 | 2022-03-01 | 君维安(武汉)生命科技有限公司 | 一种阿克曼氏菌、其培养方法及其应用 |
BE1029502B1 (fr) * | 2021-08-19 | 2023-01-17 | The Akkermansia Company | Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention de l'anxiété liée au syndrome du côlon irritable |
CN113925854B (zh) * | 2021-08-25 | 2023-06-23 | 武汉益鼎天养生物科技有限公司 | 绿原酸在制备Anaerostipes生长促进剂中的应用 |
CN114533024A (zh) * | 2021-12-30 | 2022-05-27 | 浙江大学 | 双相情感障碍生物标志物及其应用 |
CN115252749A (zh) * | 2022-03-26 | 2022-11-01 | 吉林大学 | 附子理中制剂作为抗抑郁靶向药物的应用 |
CN115300571A (zh) * | 2022-07-26 | 2022-11-08 | 深圳市第二人民医院(深圳市转化医学研究院) | 抗抑郁药物组合物及其制备方法与应用 |
CN117065002B (zh) * | 2023-02-02 | 2024-03-22 | 浙江大学 | 阿克曼菌膜蛋白Amuc_1100在预防和/或治疗年龄相关性认知下降产品制备中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101740893B1 (ko) * | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
CA2984985A1 (en) * | 2015-05-06 | 2016-11-10 | Universite Catholique De Louvain | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
CN105030841A (zh) * | 2015-08-24 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Akkermansia muciniphila BAA-835菌株的应用 |
CA3020454A1 (en) * | 2016-04-11 | 2017-10-19 | Wageningen Universiteit | Akkermansia glycaniphilus strains |
EP3551201A4 (en) * | 2016-12-06 | 2020-06-24 | Pendulum Therapeutics, Inc. | METHOD AND COMPOSITIONS RELATING TO INSULATED AND CLEANED MICROBES |
AU2017382197B2 (en) * | 2016-12-20 | 2022-12-01 | The Regents Of The University Of California | Compositions and methods for inhibiting seizures |
CN110227085A (zh) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
-
2019
- 2019-07-16 CN CN201910639110.5A patent/CN110227085A/zh active Pending
- 2019-11-18 CN CN201911126003.9A patent/CN110693917B/zh active Active
-
2020
- 2020-03-17 WO PCT/CN2020/079604 patent/WO2021008149A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110693917A (zh) | 2020-01-17 |
WO2021008149A1 (zh) | 2021-01-21 |
CN110227085A (zh) | 2019-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110693917B (zh) | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 | |
Duan et al. | Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease | |
US20210161974A1 (en) | Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract | |
Wen et al. | Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation | |
Bech-Nielsen et al. | Manipulation of the gut microbiota in C57BL/6 mice changes glucose tolerance without affecting weight development and gut mucosal immunity | |
JP2019535231A (ja) | プロピオニバクテリウム属細菌由来ナノ小胞およびその用途 | |
Bianchimano et al. | Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis | |
WO2019017389A1 (ja) | Th1細胞誘導性細菌に対する抗菌組成物 | |
EP3696284A1 (en) | Method for diagnosing alzheimer dementia via bacterial metagenomic analysis | |
JP7264531B2 (ja) | モルガネラ属細菌由来ナノ小胞およびその用途 | |
CN112533616A (zh) | 改善铁代谢和肠道微生物组健康的组合物和方法 | |
JP2021510300A (ja) | フィーカリバクテリウム・プラウスニッツィイ由来のナノ小胞およびその用途 | |
Chang et al. | Effects of mesobiliverdin IXα-enriched microalgae feed on gut health and microbiota of broilers | |
KR102008451B1 (ko) | 세균 메타게놈 분석을 통한 자폐증 진단방법 | |
Kim et al. | Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation | |
Okada et al. | First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy | |
Huang et al. | Tumor necrosis factor α1 (TNFα1) administration can disrupt barrier function and attenuate redox defense in midgut of red crucian carp (Carassius auratus red var) | |
CN116042875A (zh) | 一种用于预警ⅱ型糖尿病发生的微生物标志物及其应用 | |
CN116019839A (zh) | 乳酸肠球菌jdm1在制备预防或治疗炎症性肠病的药物中的应用 | |
KR20190094764A (ko) | 세균 메타게놈 분석을 통한 과민성장증후군 진단방법 | |
Talpin et al. | A20 in dendritic cells restrains intestinal anti-bacterial peptide expression and preserves commensal homeostasis | |
CN114028375A (zh) | 衣康酸二甲酯在制备用于预防和/或治疗肥胖诱导肠道微生态失调药物中的应用 | |
US20210247394A1 (en) | Isolated bacterial strain for inducing proliferation or accumulation of regulatory t-cells | |
JP2022516988A (ja) | デイノコッカス属細菌由来ナノ小胞及びその用途 | |
CN113209282B (zh) | 维持肠道阿克曼式菌丰度的抗菌肽的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |